MiniMed Group, Inc. (MMED) fair value: what the stock is really worth
As of Oct 22, 2026: fair value (intrinsic value) of MiniMed Group, Inc. stock $1.95, price $18.29, upside -89.3%, quality 47 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 23, 2026.
How to read this chart
8‑month range $10.80 – $23.84 · fair‑value band $1.83 – $2.06 · the $18.29 price screens above the $1.95 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 23, 2026.
Follow MiniMed Group, Inc. Common Stock in your weekly email
Every Wednesday you see whether MiniMed Group, Inc. Common Stock is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes.
Show moreShow less
The company offers technologies including insulin delivery devices, including insulin pumps and pens, continuous glucose monitors, other consumables, supplies, and related software and services.
It serves people with diabetes who require insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform includes Automated Insulin Delivery (AID) systems for glucose sensing and automated insulin dosing and administration for glycemic control and Smart Multiple Daily Injection (MDI) systems for self-administering insulin by manual injections, which include InPen, Simplera, or Guardian 4, and wraparound applications and services.
MiniMed Group, Inc. was founded in 1983 and is headquartered in Northridge, California.
Stock analysis
MiniMed Group, Inc. (MMED) currently trades at $18.29, while our model-based Fair Value estimate is $1.95, 89.3% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of $3.50 per share, and 0 of the 6 models we run sit above the $18.29 price.
Bear case: the Asset-Based group reads lowest at $1.17, and 6 of the 6 models stay below the price. Data coverage for this calculation is low.
Scenario range: $1.83 (bear) to $2.06 (bull), the price of $18.29 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
MiniMed Group, Inc. Common Stock reported revenue of $3.1B in FY2026 versus $2.2B in FY2023, a compound +11.4%/yr. Reported net income was −$331M in FY2026.
Key figures
Market cap $4.7B Mid · P/S ratio 1.55 · EPS (TTM) $−1.53 · Net margin −10.7% · Return on equity −8.7% · Return on assets (EBIT) −1.8% · Operating margin 0.5% · Revenue (TTM) $3.2B.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 15 out of 100 (low confidence).
What moves the price
For context, the median of 10 Healthcare peers we cover trades at −40% fair-value upside, at −89%, MMED screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely ($1.17 to $10.74). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear$1.83Fair Value $1.95Bull$2.06
Price $18.29 · Upside -89.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+14.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.4%
’23
’24
’25
’26
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−3.1% (2023) → 1.6% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
News mood ⓘNews mood, the average tone of recent news (72 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
AI conclusion: Independence from Medtronic enables faster progress on the diabetes pipeline, yet thin evidence and negative profitability leave little proof of durable advantage.
Main risk: Concentration of all execution risk in one therapeutic area leaves results vulnerable to reimbursement decisions and patient adherence that could stall pipeline success.
MiniMed has now finalized its separation from Medtronic via the completed exchange offer. Independence should let the company move faster on its diabetes-focused pipeline, including the patch pump filing and closed-loop algorithm. Yet the same focus also concentrates all execution risk in one therapeutic area where reimbursement and patient adherence still determine results. Will the gains from dedicated innovation outweigh the loss of any broader corporate buffer?
Compare MiniMed Group, Inc. Common Stock with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 184 stocks
Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score47 · Bottom 25%
Fair Value upside−89.3% · Bottom 25%
Profitability
Return on assets−7.2% · Bottom 25%
Net margin (12 months)−9.7% · Bottom 25%
Operating margin (12 months)0.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)16.6% · Above median
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/B1.30× · Cheaper than median
P/S (12 months)1.46× · Cheaper than median
EV/EBITDA15.4× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 21
FUTURE (revenue growth)83· sector 36
PAST (return on equity)0· sector 28
HEALTH (low debt)0· sector 96
DIVIDEND (yield)0· sector 31
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "MiniMed Group, Inc. Common Stock Fair Value". https://www.fairvalue-calculator.com/stock/MMED
Frequently asked questions
Is MiniMed Group, Inc. (MMED) overvalued or undervalued?
As of Oct 23, 2026, our model estimates a fair value of $1.95 versus a price of $18.29, about −89% upside (overvalued).
What is the fair value of MMED?
Our model-based fair value for MiniMed Group, Inc. Common Stock is $1.95 (as of Oct 23, 2026), built from audited fundamentals. The current price: $18.29.
What is the quality score of MMED?
MiniMed Group, Inc. Common Stock has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for MiniMed Group, Inc. (MMED)?
Our model-based price target is the fair value of $1.95 (as of Oct 23, 2026) from 6 valuation models. Cautious scenario $1.83, optimistic scenario $2.06. It is a calculation from audited fundamentals, not an analyst target.
What is the MiniMed Group, Inc. Common Stock stock forecast for 2026?
Our models put fair value at $1.95, about −89% upside versus a price of $18.29 (overvalued). Cautious scenario $1.83, optimistic scenario $2.06. The calculation is refreshed regularly with new filings.
What is the revenue of MiniMed Group, Inc. (MMED)?
MiniMed Group, Inc. Common Stock reported trailing-twelve-month revenue of about $3.2B (latest available figure, as of Oct 23, 2026).
What is the intrinsic value of MiniMed Group, Inc. (MMED)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For MiniMed Group, Inc. Common Stock it is $1.95 per share (as of Oct 23, 2026), against a price of $18.29. It is the blended result of 6 valuation models (cash flow, earnings, asset, dividend).
Is MiniMed Group, Inc. Common Stock stock overvalued or undervalued in 2026?
As of Oct 23, 2026, MMED trades above its calculated fair value: price $18.29, fair value $1.95, a gap of about −89% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MMED?
No. The price is what the market pays today ($18.29); the fair value is what the company's own numbers justify ($1.95). For MiniMed Group, Inc. Common Stock the two are $16.34 per share apart. That gap is exactly why we show both numbers side by side.
How much is MiniMed Group, Inc. Common Stock worth?
The market values MiniMed Group, Inc. Common Stock at about $4.7B (market capitalisation, as of Oct 23, 2026). Per share that is $18.29; our models calculate a fair value of $1.95 per share.
What do the bullish and bearish scenarios say about MMED?
Our models span a range for MiniMed Group, Inc. Common Stock: cautious scenario $1.83, base $1.95, optimistic $2.06 per share (as of Oct 23, 2026, price $18.29). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of MiniMed Group, Inc. (MMED)?
Balance-sheet figures for MiniMed Group, Inc. Common Stock (as of Oct 23, 2026): return on equity −8.7%. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
Which stocks are comparable to MiniMed Group, Inc. Common Stock?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is MiniMed Group, Inc. Common Stock stock attractive at the current price?
The data as of Oct 23, 2026: price $18.29, calculated fair value $1.95 (−89%), Quality Score 47/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MMED calculated?
We run MiniMed Group, Inc. Common Stock through 6 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1.95, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. MiniMed Group, Inc. Common Stock itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of MiniMed Group, Inc. (MMED)?
The closing price on Oct 22, 2026 was $18.29. Our model-based fair value is $1.95, about −89% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with MiniMed Group, Inc. Common Stock right now?
The price sits above even our optimistic bull case ($2.06). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder. The models converge in a tight band ($1.83 to $2.06), unusually little disagreement for a valuation.
Key figures of MiniMed Group, Inc. Common Stock
How large is the market capitalisation of MiniMed Group, Inc. (MMED)?
The market capitalisation of MiniMed Group, Inc. Common Stock is $4.7B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of MiniMed Group, Inc. (MMED)?
The price-to-sales ratio of MiniMed Group, Inc. Common Stock is 1.55 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of MiniMed Group, Inc. (MMED)?
Earnings per share at MiniMed Group, Inc. Common Stock are $−1.53. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of MiniMed Group, Inc. (MMED)?
The net margin of MiniMed Group, Inc. Common Stock is −10.7% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of MiniMed Group, Inc. (MMED)?
The return on equity (ROE) of MiniMed Group, Inc. Common Stock is −8.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of MiniMed Group, Inc. (MMED)?
On an EBIT basis the return on assets of MiniMed Group, Inc. Common Stock is −1.8% (avg 3y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of MiniMed Group, Inc. (MMED)?
The operating margin of MiniMed Group, Inc. Common Stock is 0.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at MiniMed Group, Inc. (MMED)?
Revenue at MiniMed Group, Inc. Common Stock is growing +16.6% versus a year earlier (3y avg +11.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does MiniMed Group, Inc. (MMED) generate?
The free cash flow of MiniMed Group, Inc. Common Stock is −$420M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does MiniMed Group, Inc. (MMED) hold?
MiniMed Group, Inc. Common Stock holds more cash than debt, $153M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch MiniMed Group, Inc. Common Stock in the live analysis
One click puts MiniMed Group, Inc. Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Thin data
Oct 23, 2026